Sight Sciences Amends Loan Agreement with Hercules

An update from Sight Sciences ( (SGHT) ) is now available.

On September 30, 2025, Sight Sciences, Inc. amended its Loan and Security Agreement with Hercules Capital, Inc., extending the interest-only period to February 1, 2027. The amendment reallocates a $10 million tranche, increasing the available amount to $25 million during the interest-only period, subject to Hercules’ approval, while maintaining the overall $65 million credit facility, impacting the company’s financial flexibility and potential growth.

The most recent analyst rating on (SGHT) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Sight Sciences stock, see the SGHT Stock Forecast page.

Spark’s Take on SGHT Stock

According to Spark, TipRanks’ AI Analyst, SGHT is a Neutral.

Sight Sciences faces significant financial challenges, including declining revenues and negative cash flow, which weigh heavily on its overall score. Technical indicators suggest bearish momentum, while valuation metrics are unattractive due to ongoing losses. The earnings call provided some optimism with raised guidance, but corporate events indicate strategic and operational hurdles. The company’s strong gross margin and liquidity position offer some stability, but strategic improvements are necessary for a more favorable outlook.

To see Spark’s full report on SGHT stock, click here.

More about Sight Sciences

Sight Sciences, Inc. operates in the medical technology industry, focusing on developing and commercializing innovative solutions for ophthalmology and optometry. The company’s primary products and services are designed to address unmet needs in eye care, with a particular emphasis on minimally invasive approaches.

Average Trading Volume: 117,348

Technical Sentiment Signal: Sell

Current Market Cap: $182.2M

See more insights into SGHT stock on TipRanks’ Stock Analysis page.